SK Biopharmaceuticals Co., Ltd. 326030.KS Stock
SK Biopharmaceuticals Co., Ltd. Price Chart
SK Biopharmaceuticals Co., Ltd. 326030.KS Financial and Trading Overview
| SK Biopharmaceuticals Co., Ltd. stock price | 82700 KRW |
| Previous Close | 79800 KRW |
| Open | 80400 KRW |
| Bid | 86000 KRW x N/A |
| Ask | 86100 KRW x N/A |
| Day's Range | 80300 - 86500 KRW |
| 52 Week Range | 50900 - 86500 KRW |
| Volume | 833.15K KRW |
| Avg. Volume | 134.88K KRW |
| Market Cap | 6.72T KRW |
| Beta (5Y Monthly) | 1.035928 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 KRW |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 97267 KRW |
326030.KS Valuation Measures
| Enterprise Value | 6.17T KRW |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 25.277658 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 23.228 |
| Enterprise Value/EBITDA | -59.773 |
Trading Information
SK Biopharmaceuticals Co., Ltd. Stock Price History
| Beta (5Y Monthly) | 1.035928 |
| 52-Week Change | 14.65% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 86500 KRW |
| 52 Week Low | 50900 KRW |
| 50-Day Moving Average | 71224 KRW |
| 200-Day Moving Average | 67762.5 KRW |
326030.KS Share Statistics
| Avg. Volume (3 month) | 134.88K KRW |
| Avg. Daily Volume (10-Days) | 164.84K KRW |
| Shares Outstanding | 78.31M |
| Float | 27.95M |
| Short Ratio | N/A |
| % Held by Insiders | 64.28% |
| % Held by Institutions | 11.37% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | N/A |
| Trailing Annual Dividend Yield | N/A |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -40.10% |
| Operating Margin (ttm) | -43.86% |
| Gross Margin | 86.57% |
| EBITDA Margin | -38.85% |
Management Effectiveness
| Return on Assets (ttm) | -11.41% |
| Return on Equity (ttm) | -29.30% |
Income Statement
| Revenue (ttm) | 265.82B KRW |
| Revenue Per Share (ttm) | 3394.3 KRW |
| Quarterly Revenue Growth (yoy) | 47.69% |
| Gross Profit (ttm) | 208.41B KRW |
| EBITDA | -103295410176 KRW |
| Net Income Avi to Common (ttm) | -106594041856 KRW |
| Diluted EPS (ttm) | N/A |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 255.01B KRW |
| Total Cash Per Share (mrq) | 3256.3 KRW |
| Total Debt (mrq) | 156.44B KRW |
| Total Debt/Equity (mrq) | 49.47 KRW |
| Current Ratio (mrq) | 2.449 |
| Book Value Per Share (mrq) | N/A |
Cash Flow Statement
| Operating Cash Flow (ttm) | -151459627008 KRW |
| Levered Free Cash Flow (ttm) | -112608280576 KRW |
Profile of SK Biopharmaceuticals Co., Ltd.
| Country | South Korea |
| State | N/A |
| City | Seongnam-si |
| Address | 221, Pangyoyeok-ro |
| ZIP | 13494 |
| Phone | 82 31 8093 0114 |
| Website | https://www.skbp.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
Q&A For SK Biopharmaceuticals Co., Ltd. Stock
What is a current 326030.KS stock price?
SK Biopharmaceuticals Co., Ltd. 326030.KS stock price today per share is 82700 KRW.
How to purchase SK Biopharmaceuticals Co., Ltd. stock?
You can buy 326030.KS shares on the KSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for SK Biopharmaceuticals Co., Ltd.?
The stock symbol or ticker of SK Biopharmaceuticals Co., Ltd. is 326030.KS.
Which industry does the SK Biopharmaceuticals Co., Ltd. company belong to?
The SK Biopharmaceuticals Co., Ltd. industry is Biotechnology.
How many shares does SK Biopharmaceuticals Co., Ltd. have in circulation?
The max supply of SK Biopharmaceuticals Co., Ltd. shares is 78.31M.
What is SK Biopharmaceuticals Co., Ltd. Price to Earnings Ratio (PE Ratio)?
SK Biopharmaceuticals Co., Ltd. PE Ratio is now.
What was SK Biopharmaceuticals Co., Ltd. earnings per share over the trailing 12 months (TTM)?
SK Biopharmaceuticals Co., Ltd. EPS is 0 KRW over the trailing 12 months.
Which sector does the SK Biopharmaceuticals Co., Ltd. company belong to?
The SK Biopharmaceuticals Co., Ltd. sector is Healthcare.